Recherches "plusieurs pathologies" REGOMUNE A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Saint-Cloud SEGOLENE HESCOT
Recherches "plusieurs pathologies" MOST Plus My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors Paris CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" MK7684A-005 A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Appareil Digestif TEDOPaM Prodige 63 A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Saint-Cloud
Recherches "plusieurs pathologies" SCANDARE (IC 2016-03) Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
VADS Nanoray-312 A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC Paris MARIA LESNIK
Recherches "plusieurs pathologies" ALCINA 2 Analysis of Circulating Tumor Markers in Blood Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCINA-4 (IC 2020-11) Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 Paris, Saint-Cloud LUC CABEL, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCYTA (IC 2020-12) Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA Paris, Saint-Cloud NICOLAS GIRARD, NICOLAS GIRARD
VADS BNT113-01 A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) Paris CHRISTOPHE LE TOURNEAU